Funding for this research was provided by:
Bristol Myers Squibb
Received: 8 September 2021
Accepted: 18 January 2022
First Online: 26 February 2022
: The study did not require informed consent from the patients and although also not required, the study protocol and materials were submitted to a private, centralized institutional ethics review board (Western Institutional Review Board [WIRB]), for methodological approval. Consent waiver and ethical approval was obtained from the ethics committee i.e. WIRB. The research in the study involving human participants, human material, or human data, was performed in accordance with national/international/institutional guidelines, also guidelines provided by the European Pharmaceutical Market Research Association (EPhMRA) and aligned domestic organizations, and in accordance with HIPAA guidelines, which was approved by WIRB ethics committee.
: Not applicable.
: Edward Broughton and Kyna M Gooden are employed by BMS. Ivana Rajkovic, Katie L Mycock, and Gavin Taylor-Stokes have no conflicts of interest to disclose.